By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Antidiuretic hormones > Ddavp rhinal tube (nasal) > Desmopressin Dosage
Antidiuretic hormones
https://themeditary.com/dosage-information/desmopressin-dosage-2235.html

Desmopressin Dosage

Drug Detail:Ddavp rhinal tube (nasal) (Desmopressin (nasal) [ dez-mo-press-in ])

Drug Class: Antidiuretic hormones

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Diabetes Insipidus

Initial dose: 0.05 mg orally twice a day or
1 to 2 mcg IV twice a day or
1 to 2 mcg subcutaneously twice a day or
5 to 40 mcg spray intranasally twice a day or
0.1 to 0.4 mL via rhinal tube intranasally twice a day.
The optimal dosage depends on the patient's response (duration of sleep and adequate, not excessive water turnover). The morning and evening doses should be separately adjusted for an adequate diurnal rhythm of water turnover.

Usual Adult Dose for Hemophilia A

IV: 0.3 mcg/kg once slowly over 15-30 minutes. Preoperative IV doses may be given 30 minutes prior to scheduled procedure. Blood pressure and heart rate monitoring during infusion is recommended. Repeat administration should be determined by laboratory response as well as the clinical condition of the patient.
Intranasal: 1 spray (1.5 mg/mL) in each nostril one time.
Demonstration of an adequate improvement in coagulation profile after administration is recommended prior to any surgical procedures. Preoperative doses may be given 2 hours prior to the scheduled procedure. Repeat administration should be determined by laboratory response and clinical condition of the patient.

Usual Adult Dose for von Willebrand's Disease

IV: 0.3 mcg/kg once slowly over 15-30 minutes. Preoperative IV doses may be given 30 minutes prior to scheduled procedure. Blood pressure and heart rate monitoring during infusion is recommended. Repeat administration should be determined by laboratory response as well as the clinical condition of the patient.
Intranasal: 1 spray (1.5 mg/mL) in each nostril one time.
Demonstration of an adequate improvement in coagulation profile after administration is recommended prior to any surgical procedures. Preoperative doses may be given 2 hours prior to the scheduled procedure. Repeat administration should be determined by laboratory response and clinical condition of the patient. The nasal spray should not be used to treat patients with type IIB von Willebrand's disease since platelet aggregation may be induced.

Usual Adult Dose for Primary Nocturnal Enuresis

Oral: 0.2 to 0.6 mg once before bedtime.

Usual Pediatric Dose for Diabetes Insipidus

Infants 3 months of age to children 12 years of age:
Intranasal: 5 mcg/day as a single dose or in 2 divided doses. Dose range is 5 to 30 mcg/day. The morning and evening doses should be separately adjusted for an adequate diurnal rhythm of water turnover.
Oral: 0.05 mg twice a day. Dose range is 0.1 to 0.8 mg daily.
IV and subcutaneously: No definitive dosing available. Adult dosing should not be used in this age group; adverse events such as hyponatremia-induced seizures may occur. Dose should be reduced. Some have suggested an initial dosage range of 0.1 to 1 mcg in 1 or 2 divided doses. Initiate at low dose and increase as necessary. Closely monitor serum sodium levels and urine output; fluid restriction is recommended.

Children more than 12 years of age:
Intranasal: 5 to 40 mcg/day divided into 1 to 3 doses. The morning and evening doses should be separately adjusted for an adequate diurnal rhythm of water turnover.
Oral: 0.05 mg twice daily. Dose range is 0.1 to 1.2 mg divided into 2 or 3 doses.
IV: 1 to 2 mcg twice a day
Subcutaneously: 1 to 2 mcg twice a day

Use in children requires careful fluid intake restrictions to prevent possible hyponatremia and water intoxication. The optimal dosage depends on the patient's response (duration of sleep and adequate, not excessive water turnover).

Usual Pediatric Dose for Hemophilia A

Infants 3 months of age and children:
IV: 0.3 mcg/kg by slow infusion over 15-30 minutes beginning 30 minutes before procedure. May repeat dose if needed.

Children more than 12 years of age:
IV: 0.3 mcg/kg once slowly over 15-30 minutes.
Intranasal:
50 kg or less: 150 mcg
more than 50 kg: 150 mcg in each nostril.
Demonstration of an adequate improvement in coagulation profile after administration is recommended prior to any surgical procedures. Preoperative doses may be given 2 hours prior to the scheduled procedure. Repeat administration should be determined by laboratory response and clinical condition of the patient.

Usual Pediatric Dose for von Willebrand's Disease

Infants 3 months of age and children:
IV: 0.3 mcg/kg by slow infusion over 15 to 30 minutes beginning 30 minutes before procedure. May repeat dose if needed.

Children more than 12 years of age:
IV: 0.3 mcg/kg once slowly over 15 to 30 minutes.
Intranasal:
50 kg or less: 150 mcg
More than 50 kg: 150 mcg in each nostril.
Demonstration of an adequate improvement in coagulation profile after administration is recommended prior to any surgical procedures. Preoperative doses may be given 2 hours prior to the scheduled procedure. Repeat administration should be determined by laboratory response and clinical condition of the patient. The nasal spray should not be used to treat patients with type IIB von Willebrand's disease since platelet aggregation may be induced.

Usual Pediatric Dose for Primary Nocturnal Enuresis

6 years or older:
0.2 to 0.6 mg orally once daily before bedtime.

Renal Dose Adjustments

Desmopressin is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50 mL/min).

Liver Dose Adjustments

Data not available

Precautions

When desmopressin is administered to patients who do not have need of antidiuretic hormone for its antidiuretic effect, in particular pediatric and geriatric patients, fluid intake should be adjusted downward to decrease to potential occurrence of water intoxication and hyponatremia with accompanying signs and symptoms (headache, nausea/vomiting, decreased serum sodium and weight gain). Desmopressin intranasal formulations are no longer indicated for the treatment of primary nocturnal enuresis due to the risk for developing severe hyponatremia that can result in seizures and death.

Dialysis

Data not available

Other Comments

The comparable antidiuretic dose of the injection is approximately 1/10 the intranasal dose.

Frequently asked questions

  • What is the difference in Nocdurna dosage between men and women?
  • How does Noctiva work?
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by